COVID-19 IgM – ELISA

Dia.pro COVID19 IgM

COVID-19 IgM – ELISA

INTENDED USE

Enzyme ImmunoAssay (ELISA) for the determination of IgM antibodies to COVID19 in human plasma and sera.

The kit is intended for the monitoring of the immune response to COVID-19 in the early stage of the infection as an additional marker to PCR.

For “in vitro” diagnostic use only.

 

INTRODUCTION

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first identified amid an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China and has since then caused a global pandemic. SARS-CoV-2 is a positive-sense single-stranded RNA virus and belongs to the Betacoronavirus Genus, which also includes SARS CoV (2003) and MERS CoV (2012). Same as all other coronaviruses, the genome of SARS-CoV-2 (2019-nCoV) encodes the spike protein, the envelope protein, the membrane protein, and the nucleocapsid protein. Those who are infected with COVID-19 may have little to no symptoms. Symptoms of COVID-19 are similar to a cold or flu and may take up to 14 days to appear after exposure to SARS-CoV-2. Symptoms have included: fever, cough, difficulty breathing, pneumonia in both lungs.

In severe cases, infection can lead to death. Current tests for SARS-CoV-2 look for genetic material of the virus in oral swabs, using the polymerase chain reaction (PCR). PCR only give a positive result when the virus RNA is still present.

Enzyme-linked immunosorbent assays (ELISAs) are more rapid,

easily automatable and simple tests respect PCR, providing additional markers of early COVID-19 infection.

Dia.pro COVID19 IgM